Trial reportThe American journal on addictions2023
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder.
Trial report in The American journal on addictions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 8 institutions in 1 country.
Margaret Paschen-WolffNew York State Psychiatric Institute, Department of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center, New York, New York, USA.ORCID 0000-0003-1176-5183
Kathleen BurlewDepartment of Psychology, College of Arts & Sciences, University of Cincinnati, Cincinnati, Ohio, USA.
Martina PavlicovaDepartment of Biostatistics, Columbia University Mailman School of Public Health, New York, New York, USA.
Tse-Hwei ChooMental Health Data Science Division, New York State Psychiatric Institute and Columbia University, New York, New York, USA.
Celestina Barbosa-LeikerCollege of Nursing, Washington State University, Spokane, Washington, USA.ORCID 0000-0002-5576-4150
Lesia M RuglassDepartment of Psychology, City College of New York, New York, New York, USA.
Sarah MennengaDepartment of Psychiatry, New York University Grossman School of Medicine, New York, New York, USA.
John RotrosenDepartment of Psychiatry, New York University Grossman School of Medicine, New York, New York, USA.
Edward V NunesNew York State Psychiatric Institute, Department of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center, New York, New York, USA.ORCID 0000-0002-2055-3425
Aimee N C CampbellNew York State Psychiatric Institute, Department of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center, New York, New York, USA.ORCID 0000-0003-4247-9980
New York Psychoanalytic Society and Institute · USHarvard University · USNew York University · USCity College of New York · USColumbia University · USNew York State Office of Mental Health · USUniversity of Cincinnati · USWashington State University Spokane · US
Funding
Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Clinical Trials Network: Southwest NodeU10DA015833 · NIDA · UNIVERSITY OF NEW MEXICO · PI MCCRADY, BARBARA S · 2002 to 2014
$19.9M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
Clinical Trials Network: Mid-Atlantic Integrated Care Research CollaborativeUG1DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 2015 to 2019
$11.0M
Training Program on HIV and Substance Use in the Criminal Justice SystemT32DA037801 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Nabila El-Bassel, Lisa R Metsch · 2014 to 2026
objectivesLimited research has explored sex differences in opioid use disorder medication (MOUD) treatment outcomes. The purpose of this study was to examine MOUD initiation onto buprenorphine-naloxone (BUP-NX) versus extended-release naltrexone (XR-NTX) by sex, and sex differences in clinical and psychosocial outcomes.
methodsUsing data from a 24-week open-label comparative effectiveness trial of BUP-NX or XR-NTX, this study examined MOUD initiation (i.e., receiving a minimum one XR-NTX injection or first BUP-NX dose) and 24-week self-report outcomes. We used regression models to estimate the probability of MOUD initiation failure among the intent-to-treat sample (N = 570), and the main and interaction effects of sex on outcomes of interest among the subsample of participants who successfully initiated MOUD (n = 474).
resultsIn the intent-to-treat sample, the odds of treatment initiation failure were not significantly different by sex. In the subsample of successful MOUD initiates, the effect of treatment on employment at week 24 was significantly moderated by sex (p = .003); odds of employment were not significantly different among males by MOUD type; females randomized to XR-NTX versus BUP-NX had 4.63 times greater odds of employment (p < .001). Males had significantly lower odds of past 30-day exchanging sex for drugs versus females (adjusted odds ratios [aOR] = 0.10, p = .004), controlling for treatment and baseline outcomes. DISCUSSION AND
conclusionsFurther research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women. SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.
Indexed as
Buprenorphine, Naloxone Drug CombinationNaltrexoneOpioid-Related DisordersDelayed-Action PreparationsFemaleHumansMaleTreatment OutcomeBuprenorphine, Naloxone Drug CombinationDelayed-Action PreparationsNaltrexone
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder. · full record | OpenQuestion